Acute Allograft Rejection: Cellular and Humoral Processes

Clinics in Chest Medicine

Volumn 32, Issue 2, 2011, Pages 295-310

  Martinu, Tereza ^a   Pavlisko, Elizabeth N ^a   Chen, Dong Feng ^a   Palmer, Scott M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute rejection; Antibody mediated rejection; Histocompatibility; Humoral rejection; Lung transplantation

Indexed keywords

BORTEZOMIB; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ANTIGEN RECOGNITION; BRONCHOSCOPY; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL FEATURE; DONOR SELECTION; GRAFT RECIPIENT; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; HYPOXEMIA; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LUNG GRAFT REJECTION; LUNG HEMORRHAGE; PLASMAPHERESIS; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPIROMETRY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY;

ACUTE DISEASE; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LUNG TRANSPLANTATION; RISK FACTORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 79954617293     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.02.008     Document Type: Review

References (121)

1. Christie J.D., Edwards L.B., Kucheryavaya A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010, 29(10):1104-1118.
2. Sharples L.D., McNeil K., Stewart S., et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002, 21(2):271-281.
3. Snyder L.D., Palmer S.M. Immune mechanisms of lung allograft rejection. Semin Respir Crit Care Med 2006, 27(5):534-543.
4. Lau C.L., Palmer S.M., D'Amico T.A., et al. Lung transplantation at Duke University Medical Center. Clin Transpl 1998, 327-340.
5. Sarahrudi K., Carretta A., Wisser W., et al. The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation. Transpl Int 2002, 15(1):24-28.
6. Colvin R.B., Smith R.N. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005, 5(10):807-817.
7. Magro C.M., Klinger D.M., Adams P.W., et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant 2003, 3(10):1264-1272.
8. De Vito Dabbs A., Hoffman L.A., Iacono A.T., et al. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation?. Heart Lung 2004, 33(6):372-380.
9. Van Muylem A., Melot C., Antoine M., et al. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax 1997, 52(7):643-647.
10. Gotway M.B., Dawn S.K., Sellami D., et al. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology 2001, 221(1):207-212.
11. Ng Y.L., Paul N., Patsios D., et al. Imaging of lung transplantation: review. AJR Am J Roentgenol 2009, 192(Suppl 3):S1-S13. [quiz: S14-9].
12. Hasegawa T., Iacono A.T., Yousem S.A. The anatomic distribution of acute cellular rejection in the allograft lung. Ann Thorac Surg 2000, 69(5):1529-1531.
13. Stewart S., Fishbein M.C., Snell G.I., et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007, 26(12):1229-1242.
14. McWilliams T.J., Williams T.J., Whitford H.M., et al. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant 2008, 27(11):1203-1209.
15. Valentine V.G., Gupta M.R., Weill D., et al. Single-institution study evaluating the utility of surveillance bronchoscopy after lung transplantation. J Heart Lung Transplant 2009, 28(1):14-20.
16. Hopkins P.M., Aboyoun C.L., Chhajed P.N., et al. Prospective analysis of 1235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 2002, 21(10):1062-1067.
17. Chan C.C., Abi-Saleh W.J., Arroliga A.C., et al. Diagnostic yield and therapeutic impact of flexible bronchoscopy in lung transplant recipients. J Heart Lung Transplant 1996, 15(2):196-205.
18. Kukafka D.S., O'Brien G.M., Furukawa S., et al. Surveillance bronchoscopy in lung transplant recipients. Chest 1997, 111(2):377-381.
19. Guilinger R.A., Paradis I.L., Dauber J.H., et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med 1995, 152:2037-2043.
20. Trulock E.P., Ettinger N.A., Brunt E.M., et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992, 102(4):1049-1054.
21. Chakinala M.M., Ritter J., Gage B.F., et al. Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. J Heart Lung Transplant 2004, 23(12):1396-1404.
22. Valentine V.G., Taylor D.E., Dhillon G.S., et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant 2002, 21(3):319-326.
23. Reynaud-Gaubert M., Thomas P., Gregoire R., et al. Clinical utility of bronchoalveolar lavage cell phenotype analyses in the postoperative monitoring of lung transplant recipients. Eur J Cardiothorac Surg 2002, 21(1):60-66.
24. Gregson A.L., Hoji A., Saggar R., et al. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. Transplantation 2008, 85(7):1056-1059.
25. Meehan A.C., Sullivan L.C., Mifsud N.A., et al. Natural killer cell activation in the lung allograft early post-transplantation. Transplantation 2010, 89(6):756-763.
26. Vanaudenaerde B.M., Dupont L.J., Wuyts W.A., et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006, 27(4):779-787.
27. Bhorade S.M., Yu A., Vigneswaran W.T., et al. Elevation of interleukin-15 protein expression in bronchoalveolar fluid in acute lung allograft rejection. Chest 2007, 131(2):533-538.
28. Ross D.J., Moudgil A., Bagga A., et al. Lung allograft dysfunction correlates with gamma-interferon gene expression in bronchoalveolar lavage. J Heart Lung Transplant 1999, 18(7):627-636.
29. Patil J., Lande J.D., Li N., et al. Bronchoalveolar lavage cell gene expression in acute lung rejection: development of a diagnostic classifier. Transplantation 2008, 85(2):224-231.
30. Aharinejad S., Taghavi S., Klepetko W., et al. Prediction of lung-transplant rejection by hepatocyte growth factor. Lancet 2004, 363(9420):1503-1508.
31. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82(5):663-668.
32. Bhorade S.M., Janata K., Vigneswaran W.T., et al. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008, 27(9):990-994.
33. Husain S., Raza K., Pilewski J.M., et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009, 87(12):1852-1857.
34. Huang Y., Nizami Nazih Zuhdi I. Correlation of Cylex ImmuKnow assay with lung allograft biopsy. J Heart Lung Transplant 2007, 26(2):S175.
35. De Soyza A., Fisher A.J., Small T., et al. Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am J Respir Crit Care Med 2001, 164(7):1209-1212.
36. Silkoff P.E., Caramori M., Tremblay L., et al. Exhaled nitric oxide in human lung transplantation. A noninvasive marker of acute rejection. Am J Respir Crit Care Med 1998, 157:1822-1828.
37. Tavora F., Drachenberg C., Iacono A., et al. Quantitation of T lymphocytes in post-transplant transbronchial biopsies. Hum Pathol 2009, 40(4):505-515.
38. Yousem S.A., Martin T., Paradis I.L., et al. Can immunohistological analysis of transbronchial biopsy specimens predict responder status in early acute rejection of lung allografts?. Hum Pathol 1994, 25(5):525-529.
39. Reams B.D., Musselwhite L.W., Zaas D.W., et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant 2007, 7(12):2802-2808.
40. Chakinala M.M., Ritter J., Gage B.F., et al. Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant 2005, 24(6):652-657.
41. Stephenson A., Flint J., English J., et al. Interpretation of transbronchial lung biopsies from lung transplant recipients: inter- and intraobserver agreement. Can Respir J 2005, 12(2):75-77.
42. Colombat M., Groussard O., Lautrette A., et al. Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection. Clinicopathologic correlations during the first 6 months after lung transplantation. Hum Pathol 2005, 36(4):387-394.
43. Burton C.M., Iversen M., Carlsen J., et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant 2009, 28(9):888-893.
44. Burton C.M., Iversen M., Scheike T., et al. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation 2008, 85(4):547-553.
45. DeVito Dabbs A., Hoffman L.A., Iacono A.T., et al. Pattern and predictors of early rejection after lung transplantation. Am J Crit Care 2003, 12(6):497-507.
46. Hachem R.R., Khalifah A.P., Chakinala M.M., et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005, 80(10):1406-1413.
47. Kim D.W., Dacic S., Iacono A., et al. Significance of a solitary perivascular mononuclear infiltrate in lung allograft recipients with mild acute cellular rejection. J Heart Lung Transplant 2005, 24(2):152-155.
48. Glanville A.R., Aboyoun C.L., Havryk A., et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008, 177(9):1033-1040.
49. Husain A.N., Siddiqui M.T., Montoya A., et al. Postlung transplant biopsies: an 8-year Loyola experience. Mod Pathol 1996, 9(2):126-132.
50. Irani S., Gaspert A., Vogt P., et al. Inflammation patterns in allogeneic and autologous airway tissue of lung transplant recipients. Am J Transplant 2005, 5(10):2456-2463.
51. Ward C., Snell G.I., Orsida B., et al. Airway versus transbronchial biopsy and BAL in lung transplant recipients: different but complementary. Eur Respir J 1997, 10(12):2876-2880.
52. Xu X., Golden J.A., Dolganov G., et al. Transcript signatures of lymphocytic bronchitis in lung allograft biopsy specimens. J Heart Lung Transplant 2005, 24(8):1055-1066.
53. Scholma J., Slebos D.J., Boezen H.M., et al. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2000, 162(6):2221-2225.
54. Yousem S.A. The potential role of mast cells in lung allograft rejection. Hum Pathol 1997, 28(2):179-182.
55. Schulman L.L., Weinberg A.D., McGregor C., et al. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998, 157:1833-1837.
56. Quantz M.A., Bennett L.E., Meyer D.M., et al. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000, 19(5):473-479.
57. Wisser W., Wekerle T., Zlabinger G., et al. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant 1996, 15(12):1209-1216.
58. Ruiz R., Kunitake H., Wilkinson A.H., et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006, 141(8):735-741. [discussion: 741-732].
59. Pinderski L.J., Kirklin J.K., McGiffin D., et al. Multiorgan transplantation: is there a protective effect against acute and chronic rejection?. J Heart Lung Transplant 2005, 24(11):1828-1833.
60. Keenan R.J., Bruzzone P., Paradis I.L., et al. Similarity of pulmonary rejection patterns among heart-lung and double-lung transplant recipients. Transplantation 1991, 51(1):176-180.
61. Moffatt-Bruce S.D., Karamichalis J., Robbins R.C., et al. Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?. Ann Thorac Surg 2006, 81(1):286-291. [discussion: 291].
62. Treede H., Klepetko W., Reichenspurner H., et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001, 20(5):511-517.
63. Hachem R.R., Yusen R.D., Chakinala M.M., et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007, 26(10):1012-1018.
64. Snell G.I., Valentine V.G., Vitulo P., et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006, 6(1):169-177.
65. Ahya V.N., Douglas L.P., Andreadis C., et al. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant 2007, 26(8):839-844.
66. Girnita D.M., Webber S.A., Zeevi A. Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med 2008, 28(3):423-440.
67. Zheng H.X., Burckart G.J., McCurry K., et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant 2004, 23(5):541-546.
68. Zheng H.X., Zeevi A., McCurry K., et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005, 14(1):37-42.
69. Colobran R., Casamitjana N., Roman A., et al. Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes Immun 2009, 10(3):254-259.
70. Palmer S.M., Burch L.H., Trindade A.J., et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005, 171(7):780-785.
71. Palmer S.M., Klimecki W., Yu L., et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant 2007, 7(3):693-699.
72. Shah N., Force S.D., Mitchell P.O., et al. Gastroesophageal reflux disease is associated with an increased rate of acute rejection in lung transplant allografts. Transplant Proc 2010, 42(7):2702-2706.
73. Ibrahim J.E., Sweet S.C., Flippin M., et al. Rejection is reduced in thoracic organ recipients when transplanted in the first year of life. J Heart Lung Transplant 2002, 21(3):311-318.
74. Scott J.P., Whitehead B., de Leval M., et al. Paediatric incidence of acute rejection and obliterative bronchiolitis: a comparison with adults. Transpl Int 1994, 7(Suppl 1):S404-S406.
75. Mahidhara R., Bastani S., Ross D.J., et al. Lung transplantation in older patients?. J Thorac Cardiovasc Surg 2008, 135(2):412-420.
76. Gutierrez C., Al-Faifi S., Chaparro C., et al. The effect of recipient's age on lung transplant outcome. Am J Transplant 2007, 7(5):1271-1277.
77. Kumar D., Husain S., Chen M.H., et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010, 89(8):1028-1033.
78. Kumar D., Erdman D., Keshavjee S., et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005, 5(8):2031-2036.
79. Vilchez R.A., Dauber J., McCurry K., et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003, 3(2):116-120.
80. Garantziotis S., Howell D.N., McAdams H.P., et al. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001, 119(4):1277-1280.
81. Soccal P.M., Aubert J.D., Bridevaux P.O., et al. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis 2010, 51(2):163-170.
82. Costa C., Delsedime L., Solidoro P., et al. Herpesviruses detection by quantitative real-time polymerase chain reaction in bronchoalveolar lavage and transbronchial biopsy in lung transplant: viral infections and histopathological correlation. Transplant Proc 2010, 42(4):1270-1274.
83. Bergallo M., Costa C., Terlizzi M.E., et al. Quantitative detection of the new polyomaviruses KI, WU and Merkel cell virus in transbronchial biopsies from lung transplant recipients. J Clin Pathol 2010, 63(8):722-725.
84. Astegiano S., Bergallo M., Solidoro P., et al. Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients. Transplant Proc 2010, 42(4):1275-1278.
85. Palmer S.M., Limaye A.P., Banks M., et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010, 152(12):761-769.
86. Glanville A.R., Gencay M., Tamm M., et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005, 24(2):131-136.
87. Clelland C., Higenbottam T., Stewart S., et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor. Am Rev Respir Dis 1993, 147:1386-1392.
88. Fuehner T., Simon A., Dierich M., et al. Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation. Respir Med 2009, 103(8):1114-1121.
89. Vitulo P., Oggionni T., Cascina A., et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002, 21(4):435-439.
90. Sarahrudi K., Estenne M., Corris P., et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004, 127(4):1126-1132.
91. Shennib H., Massard G., Reynaud M., et al. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant 1994, 13(3):514-519.
92. Keenan R.J., Iacono A., Dauber J.H., et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 1997, 113(2):335-340. [discussion: 340-331].
93. Iacono A., Dauber J., Keenan R., et al. Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation 1997, 64(2):263-269.
94. Dall'Amico R., Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci 2002, 26(3):197-204.
95. Valentine V.G., Robbins R.C., Wehner J.H., et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest 1996, 109(5):1184-1189.
96. Jaramillo A., Smith C.R., Maruyama T., et al. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003, 64(5):521-529.
97. Pei R., Lee J.H., Shih N.J., et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003, 75(1):43-49.
98. McKenna R.M., Takemoto S.K., Terasaki P.I. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000, 69(3):319-326.
99. Appel J.Z., Hartwig M.G., Davis R.D., et al. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 2005, 66(4):378-386.
100. Appel J.Z., Hartwig M.G., Cantu E., et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006, 81(7):1049-1057.
101. Taylor C.J., Smith S.I., Morgan C.H., et al. Selective omission of the donor cross-match before renal transplantation: efficacy, safety, and effects on cold storage time. Transplantation 2000, 69(5):719-723.
102. Girnita A.L., McCurry K.R., Iacono A.T., et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004, 23(10):1135-1141.
103. Palmer S.M., Davis R.D., Hadjiliadis D., et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002, 74(6):799-804.
104. Hadjiliadis D., Chaparro C., Reinsmoen N.L., et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005, 24(Suppl 7):S249-S254.
105. Burlingham W.J., Love R.B., Jankowska-Gan E., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007, 117(11):3498-3506.
106. Goers T.A., Ramachandran S., Aloush A., et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008, 180(7):4487-4494.
107. Masson E., Stern M., Chabod J., et al. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007, 26(6):642-645.
108. Astor T.L., Weill D., Cool C., et al. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J Heart Lung Transplant 2005, 24(12):2091-2097.
109. Badesch D.B., Zamora M., Fullerton D., et al. Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection. J Heart Lung Transplant 1998, 17(4):415-422.
110. Ionescu D.N., Girnita A.L., Zeevi A., et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol 2005, 15(1):63-68.
111. Miller G.G., Destarac L., Zeevi A., et al. Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. Am J Transplant 2004, 4(8):1323-1330.
112. Girnita A.L., McCurry K.R., Yousem S.A., et al. Antibody-mediated rejection in lung transplantation: case reports. Clin Transpl 2006, 508-510.
113. Magro C.M., Abbas A.E., Seilstad K., et al. C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction. Hum Immunol 2006, 67:274-283.
114. Westall G.P., Snell G.I., McLean C., et al. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant 2008, 27(7):722-728.
115. Saint Martin G.A., Reddy V.B., Garrity E.R., et al. Humoral (antibody-mediated) rejection in lung transplantation. J Heart Lung Transplant 1996, 15(12):1217-1222.
116. Wallace W.D., Reed E.F., Ross D., et al. C4d staining of pulmonary allograft biopsies: an immunoperoxidase study. J Heart Lung Transplant 2005, 24(10):1565-1570.
117. Magro C.M., Deng A., Pope-Harman A., et al. Humorally mediated post-transplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation 2002, 74(9):1273-1280.
118. Vo A.A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359(3):242-251.
119. Hachem R.R., Yusen R.D., Meyers B.F., et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010, 29(9):973-980.
120. Lemy A., Toungouz M., Abramowicz D. Bortezomib: a new player in pre- and post-transplant desensitization?. Nephrol Dial Transplant 2010, 25(11):3480-3489.
121. Neumann J., Tarrasconi H., Bortolotto A., et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation 2010, 89(1):125-126.